Cargando…

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells

The Bcr-Abl tyrosine kinase regulates several Bcl-2 family proteins that confer resistance to apoptosis in chronic myeloid leukemia (CML) cells. Given p53's ability to modulate the expression and activity of Bcl-2 family members, we hypothesized that targeting Bcr-Abl, Bcl-2, and p53 concomitan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Bing Z., Mak, Po Yee, Mak, Duncan H., Ruvolo, Vivian R., Schober, Wendy, McQueen, Teresa, Cortes, Jorge, Kantarjian, Hagop M., Champlin, Richard E., Konopleva, Marina, Andreeff, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741546/ https://www.ncbi.nlm.nih.gov/pubmed/26431162

Ejemplares similares

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
por: Zhou, H, et al.
Publicado: (2017)

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
por: Carter, Bing Z., et al.
Publicado: (2020)

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia
por: Jacamo, Rodrigo, et al.
Publicado: (2017)

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia
por: Mukherjee, Kaushiki, et al.
Publicado: (2017)

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
por: Wu, L. X., et al.
Publicado: (2020)

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)

Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia
por: Maifrede, Silvia, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
por: Carter, Bing Z., et al.
Publicado: (2020)

BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
por: Duy, Cihangir, et al.
Publicado: (2011)

ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation
por: Khatri, Aaditya, et al.
Publicado: (2019)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors
por: Li, Yizhu, et al.
Publicado: (2015)

TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney
por: Gooskens, Saskia L., et al.
Publicado: (2015)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

Tumorigenesis promotes Mdm4-S overexpression
por: Pant, Vinod, et al.
Publicado: (2017)

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
por: Carita, Guillaume, et al.
Publicado: (2016)

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
por: Grebien, Florian, et al.
Publicado: (2011)

IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2(+) cancer stem cells
por: Battula, Venkata Lokesh, et al.
Publicado: (2017)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis
Publicado: (1986)

Promyelocytic Blast Phase of Chronic Myeloid Leukemia, BCR-ABL1-Positive: Points to be Considered at Diagnosis
por: Kim, Bohyun, et al.
Publicado: (2021)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells
por: Joha, S, et al.
Publicado: (2012)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2
por: Ding, Jie, et al.
Publicado: (2013)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

Cup‐like blasts in an adult patient with BCR‐ABL1 positive B‐cell acute lymphoblastic leukemia
por: Wang, Zhenni, et al.
Publicado: (2022)

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
por: Li, Yajuan, et al.
Publicado: (2013)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Matrine inhibits BCR/ABL mediated ERK/MAPK pathway in human leukemia cells
por: Ma, Lingdi, et al.
Publicado: (2017)

Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib
por: Oruganti, Baswanth, et al.
Publicado: (2022)

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
por: Saiki, Anne Y., et al.
Publicado: (2014)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mnr90a3ahchlto7ulln7j2e4ka